New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salmeterol xinafoate 36.3ug equivalent to salmeterol 25 µg/dose;   - aerosol inhaler, metered dose - 25 mcg/dose - active: salmeterol xinafoate 36.3ug equivalent to salmeterol 25 µg/dose   excipient: norflurane

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - salmeterol xinafoate - pressurised inhalation, suspension - 25 microgram(s) - salmeterol

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 250 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

Malta - English - Medicines Authority

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - salmeterol xinafoate, fluticasone propionate - pressurised inhalation, suspension - salmeterol xinafoate 25 µg fluticasone propionate 125 µg - drugs for obstructive airway diseases

Malta - English - Medicines Authority

mylan ireland limited unit 35/36, grange parade, baldoyle industrial estate, dublin 13, ireland - salmeterol xinafoate, fluticasone propionate - pressurised inhalation, suspension - salmeterol xinafoate 25 µg fluticasone propionate 250 µg - drugs for obstructive airway diseases

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25 microgram/250 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salmeterol xinafoate 36.3ug equivalent to to 25 µg salmeterol base per acuation;   - aerosol inhaler, metered dose - 25 mcg/dose - active: salmeterol xinafoate 36.3ug equivalent to to 25 µg salmeterol base per acuation   excipient: dichlorodifluoromethane lecithin trichlorofluoromethane

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25/250 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25 microgram/125 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone